{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:44:25Z","timestamp":1720115065321},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.intimp.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T02:57:44Z","timestamp":1528426664000},"page":"197-203","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Emergent nanotherapies in microcrystal-induced arthritis"],"prefix":"10.1016","volume":"61","author":[{"given":"Yessica","family":"Zamudio-Cuevas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Fern\u00e1ndez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Ang\u00e9lica","family":"Mart\u00ednez-Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Mart\u00ednez-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"L\u00f3pez-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2018.06.007_bb0005","doi-asserted-by":"crossref","first-page":"98e110","DOI":"10.1016\/j.berh.2015.04.025","article-title":"Molecular mechanisms of pain in crystal-induced arthritis","volume":"29","author":"Ramonda","year":"2015","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/RHU.0000000000000416","article-title":"Detection of calcium crystals in knee osteoarthritis synovial fluid a comparison between polarized light and scanning electron microscopy","volume":"22","author":"Frallonardo","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2952","article-title":"Mechanisms of inflammation in gout","volume":"12","author":"Busso","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2018.06.007_bb0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.reuma.2009.12.010","article-title":"Synovial fluid analysis","volume":"6","author":"Mart\u00ednez-Castillo","year":"2010","journal-title":"Reumatol. Clin."},{"key":"10.1016\/j.intimp.2018.06.007_bb0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/cm402552v","article-title":"The materials science of pathological crystals","volume":"26","author":"Poloni","year":"2014","journal-title":"Chem. Mater."},{"issue":"10","key":"10.1016\/j.intimp.2018.06.007_bb0030","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/rheumatology\/kev107","article-title":"Calcium-containing crystals enhance receptor activator of nuclear factor kB ligand\/macrophage colony stimulating factor mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 pathways","volume":"54","author":"Chang","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2018.06.007_bb0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.otsr.2014.09.017","article-title":"Burden of proximal humerus fractures in the French National Hospital Database","volume":"100","author":"Maravic","year":"2015","journal-title":"Orthop. Traumatol. Surg. Res."},{"key":"10.1016\/j.intimp.2018.06.007_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/BOR.0b013e3283432d1f","article-title":"Crystals, inflammation, and osteoarthritis","volume":"23","author":"Rosenthal","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0045","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/art.39640","article-title":"Decreasing crystal-induced consternation: new methods of crystal identification","volume":"68","author":"Rosenthal","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0050","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.joca.2009.04.022","article-title":"Contribution of calcium containing crystals to cartilage degradation and synovial inflammation in osteoarthritis","volume":"17","author":"Liu","year":"2009","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.intimp.2018.06.007_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1225-0","article-title":"Osteoarthritis-associated basic calcium phosphate crystals activate membrane proximal kinases in human innate immune cells","volume":"19","author":"Corr","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2018.06.007_bb0060","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.joca.2016.07.001","article-title":"Intra-articular basic calcium phosphate and monosodium urate crystals inhibit anti-osteoclastogenic cytokine signaling","volume":"24","author":"Cunningham","year":"2016","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.intimp.2018.06.007_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0049-0172(05)80016-2","article-title":"Cholesterol crystals in synovial and bursal fluid","volume":"23","author":"Lazarevic","year":"1993","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2018.06.007_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ndt\/gft332","article-title":"Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis","volume":"29","author":"Lorenz","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.intimp.2018.06.007_bb0075","article-title":"Efficacy of anakinra for various types of crystal induced arthritis in complex hospitalized patients: a case series and review of the literature","volume":"792173","author":"Aouba","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2018.06.007_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1573403X10666140914155926","article-title":"Size matters nanotechnology and therapeutics in rheumatology and immunology","volume":"10","author":"Henderson","year":"2014","journal-title":"Curr. Rheumatol. Rev."},{"key":"10.1016\/j.intimp.2018.06.007_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12916-016-0732-1","article-title":"Gout: will the \u201cKing of Diseases\u201d be the first rheumatic disease to be cured?","volume":"14","author":"Singh","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2018.06.007_bb0090","article-title":"Updated EULAR evidence-based recommendations for the management of gout","author":"Richette","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2018.06.007_bb0095","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2018.06.007_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.medcli.2016.10.019","article-title":"Diagnosis and treatment","volume":"148","author":"Sivera","year":"2017","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.intimp.2018.06.007_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.intimp.2018.06.007_bb0110","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMra1601611","article-title":"Crystallopathies","volume":"374","author":"Mulay","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.06.007_bb0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coi.2012.12.004","article-title":"Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments","volume":"25","author":"Haneklaus","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2015.17","article-title":"Trojan horses and guided missiles: targeted therapies in the war on arthritis","author":"Ferrari","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/ar2738","article-title":"Gout. Novel therapies for treatment of gout and hyperuricemia","volume":"11","author":"Terkeltaub","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2018.06.007_bb0130","first-page":"145","article-title":"New and improved strategies for the treatment of gout","volume":"3","author":"Dubchak","year":"2010","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"10.1016\/j.intimp.2018.06.007_bb0135","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1517\/14656566.6.14.2443","article-title":"An update on the treatment options for gout and calcium pyrophosphate deposition","volume":"6","author":"Choy","year":"2005","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.intimp.2018.06.007_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1759720X11432559","article-title":"Treatment and management of pseudogout: insights for the clinician","volume":"4","author":"MacMullan","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.intimp.2018.06.007_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OARRR.S39039","article-title":"Calcium pyrophosphate crystal deposition disease: diagnosis and treatment","volume":"6","author":"Rosales-Alexander","year":"2014","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2018.06.007_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/375202","article-title":"Treatment of nongout joint deposition diseases: an update","author":"Pascart","year":"2014","journal-title":"Arthritis"},{"key":"10.1016\/j.intimp.2018.06.007_bb0160","first-page":"5","article-title":"Crystal induced arthritis: an overview","volume":"10","author":"Gupta","year":"2002","journal-title":"J. Indian Rheumatol. Assoc."},{"key":"10.1016\/j.intimp.2018.06.007_bb0165","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-012-0313-z","article-title":"Cholesterol crystals and inflammation","volume":"15","author":"Grebe","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2018.06.007_bb0170","first-page":"e106","article-title":"Intra-articular drug delivery systems for arthritis treatment","volume":"2","author":"Chen","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2018.06.007_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1573403X10666140914154816","article-title":"Nanoparticle based diagnostic imaging of inflammation in rheumatic disease","volume":"10","author":"Rogers","year":"2014","journal-title":"Curr. Rheumatol. Rev."},{"key":"10.1016\/j.intimp.2018.06.007_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2017.00006","article-title":"Silver nanoparticles: technological advances, societal impacts, and metrological challenges","volume":"5","author":"Calder\u00f3n-Jim\u00e9nez","year":"2017","journal-title":"Front. Chem."},{"key":"10.1016\/j.intimp.2018.06.007_bb0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-511X-8-6","article-title":"Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies","volume":"8","author":"Bhaskar","year":"2009","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.intimp.2018.06.007_bb0195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.intimp.2018.06.007_bb0200","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2217\/nnm.15.45","article-title":"Nanomedicine delivers promising treatments for rheumatoid arthritis","volume":"10","author":"Prasad","year":"2015","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.intimp.2018.06.007_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00011-011-0393-7","article-title":"Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases","volume":"61","author":"Szelenyi","year":"2012","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.intimp.2018.06.007_bb0210","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ejp.620","article-title":"Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats","volume":"19","author":"Arora","year":"2014","journal-title":"Eur. J. Pain"},{"issue":"11","key":"10.1016\/j.intimp.2018.06.007_bb0215","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1100\/tsw.2011.106","article-title":"Nanoparticles and inflammation","volume":"9","author":"Stevenson","year":"2011","journal-title":"Sci. World J."},{"key":"10.1016\/j.intimp.2018.06.007_bb0220","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/wnan.157","article-title":"Nanotherapeutic approaches for the treatment of rheumatoidarthritis","volume":"3","author":"Pham","year":"2011","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0225","series-title":"Dynamic Biochemistry, Process Biotechnology and Molecular Biology 3","first-page":"33","article-title":"Biodegradable nanoparticles for intra-articular therapy","author":"Dyondi","year":"2009"},{"key":"10.1016\/j.intimp.2018.06.007_bb0230","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/rheumatology\/38.9.818","article-title":"Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis","volume":"38","author":"Richards","year":"1999","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2018.06.007_bb0235","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.nano.2012.05.004","article-title":"Nanomedicines for chronic non-infectious arthritis: the clinician's perspective","volume":"8","author":"Rubinstein","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.intimp.2018.06.007_bb0240","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0245","article-title":"Artificial metalloenzyme-based enzyme replacement therapy for the treatment of hyperuricemia","author":"Liu","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.intimp.2018.06.007_bb0250","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s13346-015-0219-1","article-title":"Urate crystal degradation for treatment of gout:a nanoparticulate combination therapy approach","volume":"5","author":"Tiwari","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.intimp.2018.06.007_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185704","article-title":"The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice","volume":"12","author":"Reber","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2018.06.007_bb0260","first-page":"35","article-title":"Int Nano Lett. Albumin microparticles as the carriers for allopurinol and applicable for the treatment of ischemic","volume":"6","author":"Aganyants","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.intimp.2018.06.007_bb0265","first-page":"1746","article-title":"Polymeric nanoparticles as potential carriers for topical delivery of colchicine: development and in vitro characterization","volume":"5","author":"Khalil","year":"2014","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.intimp.2018.06.007_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1208\/s12248-008-9078-8","article-title":"Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity","volume":"11","author":"Singh","year":"2009","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.intimp.2018.06.007_bb0275","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1248\/yakushi.130.397","article-title":"Preparation and in vitro, in vivo characterization of elastic liposomes encapsulating cyclodextrin-colchicine complexes for topical delivery of colchicine","volume":"130","author":"Singh","year":"2010","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.intimp.2018.06.007_bb0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5101\/nbe.v6i4.p104-110","article-title":"De-crystallization of uric acid crystals in synovial fluid using gold colloids and microwave heating","volume":"6","author":"Kioko","year":"2014","journal-title":"Nano Biomed. Eng."},{"issue":"10","key":"10.1016\/j.intimp.2018.06.007_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21101388","article-title":"Decrystallization of crystals using gold \u201cNano-Bullets\u201d and the metal-assisted and microwave-accelerated decrystallization technique","volume":"21","author":"Thompson","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2018.06.007_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1416","article-title":"Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials","volume":"9","author":"Caster","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"Suppl. 10","key":"10.1016\/j.intimp.2018.06.007_bb0295","article-title":"Initial phase 2 clinical data of SEL-212 in symptomatic gout patients: monthly dosing of a pegylated uricase (Pegsiticase) with Svp-Rapamycin enables sustained reduction of serum uric acid levels by mitigating formation of anti-drug antibodies [abstract]","volume":"69","author":"Sands","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0300","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.12659\/MSM.899852","article-title":"Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview","volume":"22","author":"Chen","year":"2016","journal-title":"Med. Sci. Monit."},{"issue":"7","key":"10.1016\/j.intimp.2018.06.007_bb0305","doi-asserted-by":"crossref","first-page":"44330","DOI":"10.1038\/srep44330","article-title":"Synergistic degradation of a hyperuricemia-causing metabolite using one-pot enzyme-nanozyme cascade reactions","volume":"13","author":"Jung","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2018.06.007_bb0310","first-page":"5407","article-title":"Molecular targets in arthritis and recent trends in nanotherapy","volume":"26","author":"Roy","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.intimp.2018.06.007_bb0315","article-title":"Micro- and nano-carrier mediated intra-articular drug delivery systems for the treatment of osteoarthritis","author":"Zhang","year":"2012","journal-title":"J. Nanotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2018.06.007_bb0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4172\/1758-4272.1000161","article-title":"Nanomedicine in rheumatology: a new field in the diagnosis and therapy of rheumatic diseases","volume":"13","author":"Gheita","year":"2018","journal-title":"Int. J. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2018.06.007_bb0325","doi-asserted-by":"crossref","unstructured":"M\u00fcller LK, Simon J, Rosenauer C, Mail\u00e4nder V, Morsbach S, Landfester K. The transferability from animal models to humans: challenges regarding aggregation and protein corona formation of nanoparticles. Biomacromolecules 2018; 12;19(2):374\u2013385. doi: https:\/\/doi.org\/10.1021\/acs.biomac.7b01472.","DOI":"10.1021\/acs.biomac.7b01472"},{"issue":"1","key":"10.1016\/j.intimp.2018.06.007_bb0330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioeng. Transl Med."},{"issue":"2","key":"10.1016\/j.intimp.2018.06.007_bb0335","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.intimp.2018.06.007_bb0340","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1098\/rsif.2009.0285.focus","article-title":"Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases","author":"Ulbrich","year":"2010","journal-title":"J. R. Soc. Interface"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918302583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918302583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T06:22:08Z","timestamp":1571466128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918302583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":68,"alternative-id":["S1567576918302583"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2018.06.007","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergent nanotherapies in microcrystal-induced arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}